You are here

TWO ANGIOTROPINS FOR HUMAN ENDOTHELIAL CELLS HAVE BEEN PURIFIED AND THE SEQUENCE OF THE FIRST TWENTY N-TERMINAL AMINO ACIDS DETERMINED.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 5005
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1986
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Old Barn Road
Lake Placid, NY 12946
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 YOUJI SAKAGAMI
 PRINCIPAL INVESTIGATOR
 (518) 523-1250
Business Contact
Phone: () -
Research Institution
N/A
Abstract

TWO ANGIOTROPINS FOR HUMAN ENDOTHELIAL CELLS HAVE BEEN PURIFIED AND THE SEQUENCE OF THE FIRST TWENTY N-TERMINAL AMINO ACIDS DETERMINED. ONLY VERY SMALL AMOUNTS OF HOMOGEN-EOUS ANGIOTROPINS ARE AVAILABLE FROM BOVINE BRAIN, AND COMMERCIAL PRODUCTION BY CONVENTIONAL MEANS IS NOT ECONOMIC.ANALYTICAL TOOLS (ANTIBODY AND CDNA) ARE NECESSARY TO ASSESSLEVELS OF ANGIOTROPINS IN PHYSIOLOGICAL TISSUES AND FLUIDS IN HEALTH AND DISEASE. WIDE AVAILABILITY OF ANGIOTROPINS TOTHE ACADEMIC AND PHARMACEUTICAL COMMUNITIES IS NECESSARY TO UNDERSTAND THEIR CHEMISTRY AND BIOLOGY. AVAILABILITY OF ANGIOTROPINS FOR ROUTINE CULTURE OF HUMAN ENDOTHELIAL CELLS FROM BIOPSY FOR DIAGNOSTIC AND PROSTHETIC BLOOD VESSELS IS NEEDED. LONG-TERM OBJECTIVES ARE TO (1) PRODUCE ACTIVE ANGIOTROPINS AT A COMMERCIAL SCALE IN RECOMBINANT BACTERIA FOR USE BY THE ACADEMIC AND PHARMACEUTICAL COMMUNITIES; (2) DEVELOP DIAGNOSTIC KITS BASED ON ANTIBODY OR CDNA TO DETERMINE ANGIOTROPIN STATUS IN FLUIDS AND TISSUES; (3) USE INACTIVE ANALOGUES OF ANGIOTROPINS OR OTHER INHIBITORS TO BLOCK THEIR ACTIVITY IN ABNORMAL VASCULARIZATION. SPECIFIC AIMS OF THIS PHASE I STUDY ARE TO (1) PREPARE AND TEST POLY-CLONAL ANTIBODY TO SYNTHETIC AMINO ACID SEQUENCES OF ANGIO- TROPINS AND TEST ANTIBODY FOR USE IN IMMUNOASSAY; (2) IDENTIFY CLONES OF E. COLI CONTAINING ANGIOTROPIN CDNA FROM APPROPRIATE CDNA LIBRARIES; AND (3) ASSESS EXPRESSION OF OF ANGIOTROPIN ANTIGEN IN RECOMBINANT CLONES. SYNTHETIC PEPTIDES WILL BE ATTACHED TO A CARRIER PROTEIN AND INJECTED IN RABBITS TO PRODUCE ANTISERA. CDNA EXPRESSION LIBRARIES WILL BE PREPARED USING THE PHAGE VECTOR, GT11. RECOMBINANT BACTERIAL CLONES WILL BE IDENTIFIED BY SYNTHETIC OLIGO- NUCLEOTIDES COMPLEMENTARY TO N-TERMINAL AMINO ACID SEQUENCESOF ANGIOTROPINS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government